JP2022130485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022130485A5 JP2022130485A5 JP2022096360A JP2022096360A JP2022130485A5 JP 2022130485 A5 JP2022130485 A5 JP 2022130485A5 JP 2022096360 A JP2022096360 A JP 2022096360A JP 2022096360 A JP2022096360 A JP 2022096360A JP 2022130485 A5 JP2022130485 A5 JP 2022130485A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tamoxifen
- promoter
- nucleic acid
- transcriptional activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433183P | 2016-12-12 | 2016-12-12 | |
| US62/433,183 | 2016-12-12 | ||
| JP2019551508A JP7091357B2 (ja) | 2016-12-12 | 2017-12-11 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
| PCT/US2017/065597 WO2018111763A1 (en) | 2016-12-12 | 2017-12-11 | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551508A Division JP7091357B2 (ja) | 2016-12-12 | 2017-12-11 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022130485A JP2022130485A (ja) | 2022-09-06 |
| JP2022130485A5 true JP2022130485A5 (https=) | 2022-10-04 |
| JP7392043B2 JP7392043B2 (ja) | 2023-12-05 |
Family
ID=62559136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551508A Active JP7091357B2 (ja) | 2016-12-12 | 2017-12-11 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
| JP2022096360A Active JP7392043B2 (ja) | 2016-12-12 | 2022-06-15 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551508A Active JP7091357B2 (ja) | 2016-12-12 | 2017-12-11 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11408005B2 (https=) |
| EP (1) | EP3551197B1 (https=) |
| JP (2) | JP7091357B2 (https=) |
| CN (1) | CN110291200B (https=) |
| AU (1) | AU2017375630B2 (https=) |
| CA (1) | CA3045665A1 (https=) |
| MX (1) | MX2019006631A (https=) |
| WO (1) | WO2018111763A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CA2945320A1 (en) | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007426XA (en) * | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| TWI809130B (zh) | 2018-06-22 | 2023-07-21 | 美商凱特製藥公司 | 嵌合跨膜蛋白及其用途 |
| EP3820484A4 (en) * | 2018-07-10 | 2022-05-04 | Precigen, Inc. | ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF |
| CA3110922A1 (en) * | 2018-08-28 | 2020-03-05 | Immunotech Biopharm Co., Ltd. | Improved therapeutic t cell |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| JP6821230B2 (ja) * | 2019-02-04 | 2021-01-27 | 国立大学法人愛媛大学 | ＣＡＲライブラリおよびｓｃＦｖの製造方法 |
| WO2020183131A1 (en) | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| JP2022525400A (ja) * | 2019-03-13 | 2022-05-13 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | フルオレセインエーテルリン脂質またはフルオレセインエーテルリン脂質前駆体と併用した抗フルオレセインｃａｒ ｔ細胞に対する拮抗薬としてのフルオレセインナトリウム |
| WO2020219425A1 (en) * | 2019-04-25 | 2020-10-29 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias |
| WO2020257823A2 (en) * | 2019-06-21 | 2020-12-24 | Kite Pharma, Inc. | TGF-β RECEPTORS AND METHODS OF USE |
| WO2021119539A1 (en) * | 2019-12-12 | 2021-06-17 | Senti Biosciences, Inc. | Method and compositions for regulated armoring of cells |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| EP4149966A4 (en) * | 2020-05-14 | 2024-08-07 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | DOUBLE PROMOTOR SYSTEMS |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| CN115803038A (zh) * | 2020-06-08 | 2023-03-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗cd171嵌合抗原受体 |
| CN111848819A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
| JP2023545071A (ja) * | 2020-10-09 | 2023-10-26 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | Ｐｄ１キメラポリペプチドを含む方法および組成物 |
| EP4259648A4 (en) * | 2020-12-08 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric anti-EGFR antigen receptors |
| EP4291571A4 (en) * | 2021-02-12 | 2025-04-16 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Activity-inducible fusion proteins with a heat shock protein 90 binding domain |
| CA3221378A1 (en) * | 2021-04-15 | 2022-10-20 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for producing and using cell-based immunotherapies to target tumors |
| WO2022241289A2 (en) * | 2021-05-14 | 2022-11-17 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Activity-inducible fusion proteins having a transcription factor and a heat shock protein 90 binding domain |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| CN116589585B (zh) * | 2021-12-29 | 2023-11-24 | 华道(上海)生物医药有限公司 | 一种抗IL13Ra2的纳米抗体及其应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
| US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| JPH07507278A (ja) | 1992-06-01 | 1995-08-10 | ニューイングランド メディカル センター ホスピタルズ インク | Ｃｄ４３キメラ分子による細胞間相互作用の阻害 |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| GB0015119D0 (en) | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| KR100545945B1 (ko) | 2000-07-03 | 2006-01-25 | 갈라 디자인, 인크. | 발현 벡터 |
| AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| WO2002097050A2 (en) * | 2001-05-31 | 2002-12-05 | Novartis Ag | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| WO2003087338A2 (en) | 2002-04-11 | 2003-10-23 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2004092338A2 (en) | 2003-04-11 | 2004-10-28 | Diadexus, Inc. | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| US20070166318A1 (en) | 2003-05-30 | 2007-07-19 | Macina Roberto A | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| CA2532460C (en) | 2003-07-21 | 2012-04-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| CA2543329A1 (en) * | 2003-10-24 | 2005-05-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Orthogonal gene switches |
| WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US7935510B2 (en) * | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| JP2009521474A (ja) | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| US8148129B2 (en) * | 2006-06-30 | 2012-04-03 | The Regents Of The University Of California | Generation of potent dominant negative transcriptional inhibitors |
| WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US8450112B2 (en) | 2008-04-09 | 2013-05-28 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| CA2738472A1 (en) | 2008-09-26 | 2010-04-22 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| EP2438443A4 (en) | 2009-06-02 | 2012-07-25 | Targeted Molecular Diagnostics Llc | METHOD FOR DETECTING AND QUANTIFYING THE P95 COMPONENT OF HER2 / NEU (ERBB2) |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| EP2697367B1 (en) | 2011-04-13 | 2018-12-19 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| EA201400046A1 (ru) | 2011-06-22 | 2014-07-30 | Ф. Хоффманн-Ля Рош Аг | Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| ITRM20120058A1 (it) | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| CA3205751A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| US20140056868A1 (en) | 2012-05-30 | 2014-02-27 | University of Washington Center for Commercialization | Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| US9792559B2 (en) | 2012-06-01 | 2017-10-17 | Nec Corporation | Switching system, line card, switch card, FDB learning method, FDB learning arbitration method and program |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| AU2013327136A1 (en) | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| CN105339498A (zh) | 2013-03-07 | 2016-02-17 | 贝勒医学院 | 癌症中靶向cd138 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US20160296562A1 (en) | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| US20160333108A1 (en) | 2014-01-13 | 2016-11-17 | Stephen J. Forman | CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| CA2945320A1 (en) | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| ES2879700T3 (es) | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
-
2017
- 2017-12-11 CN CN201780086283.8A patent/CN110291200B/zh active Active
- 2017-12-11 US US16/467,015 patent/US11408005B2/en active Active
- 2017-12-11 AU AU2017375630A patent/AU2017375630B2/en active Active
- 2017-12-11 WO PCT/US2017/065597 patent/WO2018111763A1/en not_active Ceased
- 2017-12-11 EP EP17881828.2A patent/EP3551197B1/en active Active
- 2017-12-11 MX MX2019006631A patent/MX2019006631A/es unknown
- 2017-12-11 JP JP2019551508A patent/JP7091357B2/ja active Active
- 2017-12-11 CA CA3045665A patent/CA3045665A1/en active Pending
-
2022
- 2022-06-15 JP JP2022096360A patent/JP7392043B2/ja active Active
- 2022-06-20 US US17/807,774 patent/US20220411805A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022130485A5 (https=) | ||
| US20250388929A1 (en) | Retroviral and Lentiviral Vectors | |
| JP2020500563A5 (https=) | ||
| US20240093232A1 (en) | Retroviral And Lentiviral Vectors | |
| CN107735407B (zh) | 治疗剂 | |
| CN111246861A (zh) | 扩增表达重组受体的细胞的试剂 | |
| AU2023282226A1 (en) | Polypeptide compositions comprising spacers | |
| JP2020074776A5 (https=) | ||
| JPWO2020051374A5 (https=) | ||
| CN116334113A (zh) | 有条件活性的异二聚体多肽及其使用方法 | |
| EP3995142A2 (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
| JP2019514393A (ja) | 細胞に基づくネオ抗原ワクチンおよびその使用 | |
| Sadelain | T-cell engineering for cancer immunotherapy | |
| JP2021511041A5 (https=) | ||
| JP2019513394A5 (https=) | ||
| Moot et al. | Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors | |
| RU2018140056A (ru) | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена | |
| JP2018506995A5 (https=) | ||
| JP2021513337A5 (https=) | ||
| CN114502188A (zh) | 人工免疫监视嵌合抗原受体及其表达细胞 | |
| AU2024202681A1 (en) | IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy | |
| WO2023015310A2 (en) | T-cell manufacturing methods | |
| JPWO2020245343A5 (https=) | ||
| KR20240100489A (ko) | 자가면역질환을 치료 또는 예방하기 위한 조성물 및 방법 | |
| Perez et al. | Selective immunotargeting of diabetogenic CD 4 T cells by genetically redirected T cells |